TriSalus Life Sciences (TLSI) EBIT Margin (2022 - 2026)

TriSalus Life Sciences' EBIT Margin history runs 5 years deep, the most recent figure standing at 94.52% for Q1 2026.

• On a quarterly basis, EBIT Margin fell 1457.0% year-over-year to 94.52% in Q1 2026; TTM through Mar 2026 was 62.45%, a 3656.0% increase from a year earlier, with the FY2025 full-year figure at 59.68%, up 6320.0% from the prior year.
• EBIT Margin fell to 94.52% in Q1 2026 per TLSI's latest filing, from 24.77% in the prior quarter.
• Across five years, EBIT Margin topped out at 24.77% in Q4 2025 and bottomed at 364.91% in Q4 2022.
• The 5-year median for EBIT Margin is 118.91% (2024), against an average of 174.09%.
• Across the five-year window, EBIT Margin sank 15173 bps in 2023 and jumped 23957 bps in 2024, its largest moves.
• Year by year, EBIT Margin stood at 364.91% in 2022, then jumped by 32 bps to 249.05% in 2023, then jumped by 63 bps to 91.76% in 2024, then surged by 73 bps to 24.77% in 2025, then slumped by 282 bps to 94.52% in 2026.
• Per Business Quant, the three latest TLSI EBIT Margin figures stand at 94.52% (Q1 2026), 24.77% (Q4 2025), and 77.94% (Q3 2025).